| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Adlai Nortye Ltd. American Depositary Shares$10.1
-0.16 (-1.56%)
C 45Pipeline Score Fair Value Biotech · Clinical
Market Cap
411.81 M
EPS
-
P/E Ratio
-
Value Trade
2.50 M
%
Week
%
1 Month
%
3 Month
%
6 Month
%
5 Year
%
All Time
Cash Data
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
Overview
Volume
42.96 K
52 Week Range
0.88 - 12.15
% held by Insiders
9.36 %
% held by Institutions
24.24 %
Enterprise Value
414.40 M
Total Shares
31.24 M
Short %
10.31 %
Float Shares
28.02 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
C45
Pipeline Score $940M
Pipeline ValueFair Value
Valuation Signal7
Drugs Scored2.3x
rNPV / MCap Top 69%
Micro Cap (rank 282 of 905)
Percentile RankAdlai Nortye Ltd. American Depositary Shares carries a moderate pipeline score (45/100), with $4.6B risk-adjusted pipeline value, led by AN2025 in Locally Advanced Solid Tumor (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AN4005-dose level 0 Small molecule | Advanced Solid Tumor | Phase 1 | NCT04999384 | 5% | $1.6B | RECRUITING | 31 | STALLED | B (61) | Dec 1, 2026 | LOW_RISK | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in ANL
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
ANL
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ANL
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ANL
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ANL Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
ANL Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-ANL
Apr 16, 2026Adlai Nortye Announces $150.0 Million Private Placement Equity Financing
Adlai Nortye Ltd. has announced a private placement equity financing expected to raise approximately $150 million. The oversubscribed transaction involves participation from both new and existing institutional investors. The funds will support the development of the company's innovative cancer therapies, including RAS-targeting treatments. The private placement is set to close on April 17, 2026, pending customary conditions.
Read more →-ANL
Feb 12, 2026Adlai Nortye Announces First Patient Enrolled in Global Phase 1 Trial of Pan-RAS (ON) Inhibitor AN9025 for Solid Tumors Harboring RAS Mutations
Adlai Nortye has initiated a Phase 1 clinical trial for AN9025, a pan-RAS inhibitor, with the first patient dosed in the U.S. This trial aims to assess the safety and efficacy of AN9025 in patients with solid tumors harboring RAS mutations. The study is part of a multi-regional collaboration with Jiangsu Aosaikang Pharmaceutical Co. Ltd.
Read more →-ANL
Feb 3, 2026Adlai Nortye Announces $140.0 Million Private Placement Equity Financing
Adlai Nortye Ltd. has announced a successful private placement equity financing, raising approximately $140 million. The financing involves the sale of Class A ordinary shares, co-led by Cormorant Asset Management and Columbia Threadneedle Investments. The funds will support the development of the company's innovative cancer therapies, particularly in RAS-targeting and next-generation immunotherapies.
Read more →-ANL
Dec 29, 2025Adlai Nortye Enters Exclusive License Agreement with ASK Pharm for Pan-RAS (ON) Inhibitor AN9025 in Greater China
Adlai Nortye has entered an exclusive licensing agreement with ASK Pharm for its pan-RAS (ON) inhibitor AN9025, granting ASK rights to develop and commercialize the drug in Greater China. The deal includes potential earnings of up to RMB 1.6 billion, with an upfront payment and milestone payments. This collaboration aims to accelerate the development of AN9025, which has shown promise in preclinical studies against RAS-mutant cancers.
Read more →Competitive Position
How ANL ranks across every disease it competes inCompetitive Position is a premium feature
See how ANL ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial